USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

• US 20080051429A1
• Filed: 04/18/2007
• Published: 02/28/2008
• Est. Priority Date: 04/19/2006
• Status: Abandoned Application

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Davis, Robert, Weiner, David, van Kammen, Daniel, Brann, Mark
• Application Number:
  US11/737,097
• Publication Number:
  US 20080051429A1
• Time in Patent Office: Days
• US Class Current: 514/315
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.

Claims

1. A method of increasing slow-wave sleep comprising administering N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to a subject in need of increased slow wave sleep in an amount sufficient to increase slow wave sleep.

2. The method of claim 1, wherein the administration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide comprises oral administration.

3. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 0.5 mg to about 50 mg.

4. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 1 mg to about 40 mg.

5. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 2.5 mg to about 30 mg.

6. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 5 mg to about 20 mg.

7. The method of claim 1, wherein the administration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide does not affect a sleep parameter selected from the group consisting of sleep period time, total sleep time, sleep onset latency, number of stage shifts, total time awake, early morning wake, sleep efficiency index, microarousal index, and a REM sleep parameter.

8. The method of claim 7, wherein the REM sleep parameter is selected from the group consisting of REM sleep duration, proportion of REM sleep, REM sleep latency, REM activity and REM density.

9. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 2 ng/mL to about 60 ng/mL.

10. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 4 ng/mL to about 50 ng/mL.

11. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 6 ng/mL to about 40 ng/mL.

12. The method of claim 1, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 8.5 ng/mL to about 35 ng/mL.

13. The method of claim 1, wherein the subject is administered N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide once every day.

14. The method of claim 1, wherein the subject is administered a first dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide at least 24 hours prior to administration of a second dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide.

15. The method of claim 14, wherein the first dosage form comprises a higher dose of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide than the second dosage form.

16. The method of claim 1, further comprising informing the subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide increases slow wave sleep.

17. The method of claim 16, wherein the informing comprises providing printed matter that advises that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide increases slow wave sleep.

18. The method of claim 17, wherein the printed matter is a label.

19. The method of claim 1, wherein N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is administered at a time other than immediately before a sleep period.

20. The method of claim 19, wherein N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is administered in the morning.

21. A method of treating insomnia comprising administering N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to a subject suffering from insomnia in an amount sufficient to ameliorate insomnia.

22. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 0.5 mg to about 50 mg.

23. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 1 mg to about 40 mg.

24. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 2.5 mg to about 30 mg.

25. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is in the range of about 5 mg to about 20 mg.

26. The method of claim 21, wherein the administration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide does not affect a sleep parameter selected from the group consisting of sleep period time, total sleep time, sleep onset latency, number of stage shifts, total time awake, early morning wake, sleep efficiency index, microarousal index, and a REM sleep parameter.

27. The method of claim 26, wherein the REM sleep parameter is selected from the group consisting of REM sleep duration, proportion of REM sleep, REM sleep latency, REM activity and REM density.

28. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 2 ng/mL to about 60 ng/mL.

29. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 4 ng/mL to about 50 ng/mL.

30. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 6 ng/mL to about 40 ng/mL.

31. The method of claim 21, wherein the amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide results in a steady state blood plasma concentration of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in the range of about 8.5 ng/mL to about 35 ng/mL.

32. The method of claim 21, wherein the subject is administered N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide once every day.

33. The method of claim 21, wherein the subject is administered a first dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide at least 24 hours prior to administration of a second dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide.

34. The method of claim 33, wherein the first dosage form comprises a higher dose of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide than the second dosage form.

35. The method of claim 21, further comprising informing the subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide ameliorates insomnia.

36. The method of claim 35, wherein the informing comprises providing printed matter that advises that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide ameliorates insomnia.

37. The method of claim 36, wherein the printed matter is a label.

38. The method of claim 21, wherein N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is administered at a time other than immediately before a sleep period.

39. The method of claim 38, wherein N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide is administered in the morning.

40. A method for decreasing the number of awakenings after sleep onset comprising administering N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to a subject in need of a decreased number of awakenings after sleep onset in an amount sufficient to decrease the number of awakenings after sleep onset.

41. A method for decreasing the time awake after sleep onset comprising administering N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to a subject in need of decreased time awake after sleep onset in an amount sufficient to decrease time awake after sleep onset.

42. A method of manufacturing a pharmaceutical composition, said method comprising:

obtaining a first dosage form comprising a first amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide;

obtaining a second dosage form comprising a second amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide; and

packaging together said first dosage form and said second dosage form.

43. The method of claim 42, wherein the first dosage form and the second dosage form each comprise an oral dosage form.

44. The method of claim 42, wherein the first dosage form comprises a higher dose of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide than the second dosage form.

45. A packaged pharmaceutical composition, comprising N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in a container and instructions for using N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to treat insomnia.

46. A packaged pharmaceutical composition, comprising N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide in a container and instructions for using N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide to increase slow wave sleep, decrease the number of awakenings after sleep onset or decrease the time awake after sleep onset.

47. A kit comprising a first dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide and a second dosage form of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide.

48. The kit of claim 47, wherein the first dosage form contains a higher dose of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide than the second dosage form.

49. The kit of claim 47, wherein the kit further comprises instructions for taking the first dosage form at least 24 hours before taking the second dosage form.

50. The kit of claim 47, wherein the instructions are on a label.

51. The kit of claim 50, wherein the instructions further inform a subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide increases slow wave sleep.

52. The kit of claim 47, wherein the instructions further inform a subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide ameliorates insomnia.

53. The kit of claim 47, wherein the instructions further inform a subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide decreases the number of awakenings after sleep onset.

54. The kit of claim 47, wherein the instructions further inform a subject that N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′

-(4-(2-methylpropyloxy)phenylmethyl)carbamide decreases the time awake after sleep onset.